David Kass

Backlash Against Eye-Popping Drug Prices

Martin Shkreli became the Internet villain of the fall (some publications used much harsher language) when his company, Turing Pharmaceuticals, acquired the rights to Daraprim, which treats a condition called toxoplasmosis — and promptly raised the per-pill price from $13.50 to $750. The move was entirely legal, but a bipartisan U.S. Senate committee is looking into what one senator called "price gouging" in the industry. Read more...

A Consumer Goods Behemoth Faces Pressure

Is it time for the biggest consumer products group in the world to be broken up? Procter & Gamble may account for more than half of the market for laundry care in the United States (Tide, Gain, Downy), more than two-thirds of the market for razors and blades (Gillette), and 15.5 percent of the beauty and personal care market (Pantene, and on and on). That's added up to a market capitalization of more than $200 billion. But P&G’s sales have dropped by nearly 9 percent since 2012. Smith School professor David Kass shares insights. Read more...

Deutsch Bank ‘Cleaning Slate’ for $7B Loss

Europe’s biggest investment bank is bracing for a near-$7 billion third-quarter loss, and the fallout is taking shape. Deutsche Bank will sell a credit portfolio estimated at $250 billion. The bank’s board also will recommend "a reduction or possible elimination" of the stock's dividend. Smith School professor David Kass shares insights with Bloomberg and other media outlets. Read more...

Berkshire Mega-Deal Typifies Buffett’s Bargain Hunting

Berkshire Hathaway’s $32.6 billion buyout of Precision Castparts Corp. represents the Warren Buffett conglomerate’s largest-ever takeover. But it also “exemplifies Buffett’s determination to find cheap and out-of-favor companies with a history of strong earnings and high barriers to competition,” reports the Omaha World-Herald, paraphrasing Smith School professor David Kass. Read more...

Pages

Subscribe to RSS - David Kass